Table 2 Univariate and multivariate hazard ratios for OS after liver resection for CRLM

Gene mutation

TP53

1.04 (0.74–1.46)

p = 0.814

APC

0.63 (0.47–0.84)

p = 0.002

0.57 (0.41–0.78)

p = 0.001

RAS

1.95 (1.48–2.58)

p < 0.001

1.88 (1.35–2.61)

p < 0.001

FLG

1.07 (0.75–1.51)

p = 0.722

TCF7L2

0.99 (0.67–1.46)

p = 0.952

SMAD4

1.51 (1.05–2.15)

p = 0.025

1.52 (1.03–2.23)

p = 0.034

PIK3CA

1.80 (1.21–2.68)

p = 0.004

1.40 (0.89–2.21)

p = 0.148

LRP1B

0.65 (0.39–1.08)

p = 0.093

0.71 (0.41–1.24)

p = 0.233

FBXW7

1.00 (0.65–1.55)

p = 0.982

FAT4

1.19 (0.78–1.81)

p = 0.411

ZFHX3

1.16 (0.79–1.71)

p = 0.454

SOX9

0.93 (0.58–1.49)

p = 0.767

Patient factors

Age, > 65

1.00 (0.70–1.41)

p = 0.979

Sex, male

0.72 (0.54–0.96)

p = 0.025

0.87 (0.63–1.20)

p = 0.385

Clinicopathologic factors

Primary site

Left colon and rectum

Right colon

Reference

1.38 (0.97–1.96)

p = 0.073

Reference

1.06 (0.71–1.61)

p = 0.766

Lymph node status of primary tumor

Negative

Positive

Reference

1.66 (1.20–2.30)

p = 0.002

Reference

1.50 (1.06–2.12)

p = 0.021

T stage

T1-2

T3-4

Reference

1.93 (1.02–3.64)

p = 0.044

Reference

1.37 (0.71–2.65)

p = 0.347

Disease-free interval, < 12months

1.55 (1.10–2.28)

p = 0.012

1.31 (0.89–1.93)

p = 0.175

Number of CRLM, >1

1.82 (1.30–2.55)

p = 0.001

1.63 (1.10–2.42)

p = 0.015

Largest diameter of CRLM, > 36 mm

1.3 (0.96–1.8)

p = 0.095

1.26 (0.90–1.77)

p = 0.186

Preoperative CEA, > 44ng/ml

1.65(1.16–2.35)

p = 0.005

1.13 (0.76–1.68)

p = 0.544

Response to chemotherapy

PR

Reference

no preoperative chemotherapy

0.57 (0.35–0.94)

p = 0.028

0.76 (0.43–1.35)

p = 0.350

SD

1.44 (1.05–1.97)

p = 0.023

1.39 (0.98–1.97)

p = 0.066

PD

3.32 (1.93–5.74)

p < 0.001

3.14 (1.63–6.05)

p = 0.001

Resection margin

R0

R1

Reference

1.26 (0.89–1.78)

p = 0.189

Major hepatectomy

No

Reference

Reference

Yes

1.70 (1.25–2.32)

p < 0.001

1.48 (1.05–2.09)

p = 0.027